Device China DeviceChina - Home 中文版 zhuce showcase Frequently Asked Questions camdi.org 主页 English Language 注册参会 路演报名 疑问解答

2017 ORGANIZING COMMITTEE

line
Kewen JinKewen Jin
Managing Partner, SERICA CAPITAL
Chairman, THE BAYHELIX GROUP
Serica Capital
Junyong PangJunyong Pang
CEO
BIOBAY
David WangDavid Wang
Senior Managing Director
ORBIMED
Jie WangJie Wang
EVP, Academy of Clincial Research and Translational Medicine
JIANGSU PROVINCIAL HOSPITAL
Qingsheng (Ching) ZhuQingsheng (Ching) Zhu
Managing Partner
6 Dimensions Capital
FengJiangFeng Jiang
Executive Vice President
China Association for Medical Devices Industry
 

FOUNDERS

line

Leon ChenLeon Chen
CEO & Founding Partner
6 Dimensions Capitalr


Leon Chen is the Founder and Managing Partner of Frontline BioVentures. In May, 2017, Frontline BioVentures (Frontline) and WuXi Healthcare Ventures (WuXi Ventures) merged to form 6 Dimensions Capital - one of the largest healthcare focused investment group with unique capability and extensive coverage across China and the US. Dr. Leon Chen became 6 Dimensions Capital’s CEO. Before founding Frontline BioVentures in 2012, Leon was a Partner with Fidelity Growth Partners Asia, and a Managing Partner with BioVeda China. Since 2005, Leon has led a number of investments in the life science sector in China including CITIC Pharmaceuticals, Hile Biopharma, Hua Medicine, Innovent Biologics, Adagene, MDDF, TenNor Therapeutics, Coherent Biopharma, Guoke Hengtai, Yikon Genomics, X Genomics, Bio Kangtai and Neusoft Medical.
Leon was a management consultant and a business adviser to Pharmaceutical and Biotech companies, past affiliations include McKinsey & Company, Ernst & Young LLP Leon also worked as a research scientist at Schering-Plough in New Jersey. He was a member of the discovery team of “VYTORIN”/”ZETIA” – now a multibillion dollar drug.
He received a BS degree from Peking University, a Ph.D. degree with top honor from Catholic University of Louvain, and was a Post-Doc Fellow at the Massachusetts Institute of Technology. Leon holds 6 issued US Patents and co-authored the 14th and 15th Ernst & Young Biotechnology Report.

 

Kewen JinKewen Jin
Managing Partner, SERICA CAPITALChairman THE BAYHELIX GROUP
Serica Capital


Kewen Jin is a serial entrepreneur and investor in the China life science industry. He is currently Managing Partner / co-founder of Serica Capital, a China-based medtech fund. Over the last 15 years, Kewen has co-founded and served as CEO / key executives of several companies in CRO, drug development , and medical device, most recently co-founder / CEO of SyMap, a leading device company in the Renal Denervation for Hypertension area. 
He has served as an advisor to numerous pharmaceutical / medtech companies, consulting / investment firms, notably Gates Foundation and Advent, the global PE. He advised two leading life science parks in China, Shanghai Zhangjiang and Suzhou Biobay, in developing and implementing strategic plan. He was the founding Chair of the Shanghai CRO Association. 
He was a marketing and international operation executive with Wyeth from 1993 to 2000, in the U.S. and China. 
He is currently the Chairman of Board of The BayHelix Group, an organization of Chinese life sciences business leaders in China and the U.S.
He was trained in medicine (Shanghai Jiaotong University School of Medicine), molecular biology (Rockefeller), and finance (Columbia).

 

James LiJames Li
Vice President & General Manager, Greater China
AMGEN


Dr. James Li is the Vice President and General Manager, Amgen China where he is leading company's efforts in expanding business into Chinese market and help Chinese patients to access Amgen's vital medicines. 
Prior to joining Amgen, James was a Partner at Kleiner Perkins Caufield & Byers life science practice, first in the US Pandemic Fund and later, in its China Fund. He successfully invested in a number of early stage and growth stage companies, and led a portfolio company went to public in 2010. 
From 1991 to 2006, James spent over 15 years with Merck Co. & Inc. where he held leadership positions with increasing responsibilities in clinical research, regulatory affairs, new product development and franchise management, both in the US and Asia Pacific/China. During his tenure, he was instrumental in obtaining regulatory approvals of Merck vaccines across Asia Pacific Region when the Vaccine Division started operations in the region, successfully built the foundations of Merck's medical operations in China and drove the success of Merck's largest franchise in Asia. 
James received his Medical Degree from Shanghai Medical University, followed by a Master of Science degree in Microbiology from the University of Montana.

 

Albert LimAlbert Lim
President
SONOVA


Mr. Albert LIM is currently the Vice President of Asia Pacific, SONOVA. He used to be the Vice President of Business Operations at Medtronic (Shanghai) Co., Ltd. Mr. Lim has been in the role since July 2009, responsible for Sales & marketing training, Medical education, Patient education, Channel management; Quality management, Manufacturing, Supply chain management and also responsible for the management of Medtronic Taiwan. Mr. Lim had been the Managing Director of Medtronic Taiwan from 2008. 
Albert brings with him more than 20 years of working experience in Asia. He has spent a large of part of time in the Greater China region working in both the pharmaceutical and medical device industries. 
Starting with a Bachelor Degree of Engineering in Chemical Engineering from Singapore in 1984, Mr. Lim has extensive working experience in different MNC subsidiaries in the Asia healthcare including Novartis, Abbott and MSD.

 

Yuwen LiuYuwen Liu
Founding Partner
BOHE ANGEL FUND


Founding Partner of Bohe Angel Fund, a 200M RMB fund jointly invested by Wuxi Apptec, Hengrui, Simcere, TigerMed and BGI, etc. 
Before she set up this angel fund, she was Executive Director of Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY) and chairwoman & CEO for 9 years. When she was also Investment Committee Member for BioVENTURE and Board Director of Innovent, Admera, Chiral Quest, GenePharma, Reproposing and BrightGene, and Chairwoman of Qiagen (Suzhou) Translational Medicine and Suzhou BioTOP Biotech. She joined the company as EVP in 2005, was instrumental in building BioBAY to be one of the fastest growing biotech clusters serving ~400 biotech startup companies. 
She started her career as QA Engineer for Capsugel in 1997, then moved up to QC manager, QA/QC manager and BD manager until joined Perrigo as first China Chief Representative in 2003. 
Yuwen graduated from China Pharmaceutical University with master degree in Pharmaceutics and Master of Management at Fudan University and Norwegian Management School BI, and is a licensed pharmacist.

 

David WangDavid Wang
Senior Managing Director
ORBIMED


Dr. David Wang is a Senior Managing Director at OrbiMed Asia. Most recently, he was a Managing Director at WI Harper Group, responsible for healthcare investment in China. Previously, he served as Head of Business Development at Siemens Medical Solutions, where he directed corporate strategy and new businesses in molecular diagnostics and diagnostic imaging. He was co-founder and EVP at First Genetic Trust, a personalized medicine company. During his tenure at Bristol-Myers Squibb, he was Chairman of The SNP Consortium Management Committee, the first group of its kind formed by pharmaceutical and technology industries to support the development of personalized medicine. He received his MD from Peking University Medical School. He earned his doctorate in Developmental Biology from California Institute of Technology.

 

Jie WangJie Wang
EVP, Academy of Clincial Research and Translational Medicine
JIANGSU PROVINCIAL HOSPITAL


Dr. Wang is an established and well known expert in cardiovascular research and the industry. Dr. Wang' has major contributions to both pharmacology and device therapies for cardiovascular diseases and he was leading one of the most famous heart failure research laboratories in American where he made a systematic, multi-faceted research on the many major problems of heart failure. Pathogenesis, he revealed the heart failure of vascular endothelial cell damage and calcium ion "leakage" leaving the heart dysfunction, giving the treatment of heart failure a new path. In the experimental study, he successfully established of a series of heart failure model for the pharmaceutical and medical device industry that is a very strong condition widely used to study the pathogenesis of heart failure and treatment. In the treatment, he developed a number of treatment methods, such as in drug therapy, in-depth research and development of cytokine blockers, erythropoietin and heart rate reduction compounds on the treatment of heart failure and mechanism; in cell therapy he used human stem cells and Autologous bone cell transplantation, prevention of myocardial cell dying and reconstructing the structure of the heart to treat heart failure; in gene biotherapy, he used of a special carrier GAM to carry a variety of growth factor combinations in the treatment of myocardial infarction and heart failure; in the treatment of equipment, he used left ventricular prophylaxis devices, cardiac passive auxiliaries, cardiac systolic reinforcements, and a variety of vascular stents such as left ventricular coronary stents. He has served as a consultant to companies such as Lilly, Bayer, EntreMed, Glaxo and Principal Counselor of Easton Associates, a well-known consulting firm for biomedical / medical devices. In the year of1997 to 1998, he worked as one of the main staff involved and contributed to the traditional Chinese medicine "Danshen dripping pills" and "ginkgo tablets" declaration work in the United States FDA.
He is the one of the first oversea scholars introduced the recombinant DNA pharmaceutical industry into China and set up in Shandong Jinlu biopharmaceutical company in 1993, which is for the production of recombinant DNA drugs, and then successfully sold to listed companies. In 2000, he was one of the first scholars that brought cardiovascular equipment into China to develop and produce, participated in the establishment of Suzhou Veken Medical Devices and Tianjian medical operation, where there are several products have entered the market. He has a good reputation in the industry, and a wide range of contacts in biomedical technology venture capital industry. He has initiated and participated in more than 10 new technology research and development companies. He was involved in the treatment of hypertension in the United States that has obtained the United States 2011 Edison Invention Award by the American Heart Association (AHA) and Cardiology Physicians (ACC) as decades of significant progress in the treatment of cardiovascular disease. Ardian was high-priced acquisition by the United States Dayton for the usage of the same technology and equipment by the end of 2010. He was awarded the US Cardiovascular Research Technology Award for Best Invention Award ("CRT2012 Best Innovation Award") for the development of renal biopsy positioning technology in 2012 with others as CHF Solution (acquired by Jinbao), Impulse Dynamic (Johnson & Johnson and Medtronic Investment), Cardiac Concepts (Abbott Investment).

 

Qingsheng (Ching) ZhuQingsheng (Ching) Zhu
Managing Partner
6 Dimensions Capital


Dr. Zhu is a Managing Partner of 6 Dimensions capital. He has over 20 years of experience in the Medical Device Industry as a researcher,product developer, a serial entrepreneur and a venture capitalist. His past affiliations include: Taligenix (Co-founder and CEO); ResQ Inha-Pharma (Co-founder); Action Medical (Founder, Chairman and CEO), a venture funded medical device company developing novel stimulation therapies to treat heart failure. Action Medical was acquired by Boston Scientific in April 2009; Novitas Capital (Partner). Dr. Zhu spent 10 years at Guidant Corporation (now part of Boston Scientific, Program Manager of Emerging Therapy Research). Dr. Zhu was selected by the Central HR as a Thousand Talent Expert in 2011. Dr. Zhu obtained a BS in Electronics and Physics from the Shanghai Eastern China Normal University, an MS in Medical Engineering from University of Aberdeen, Ph.D. and PostDoc in Biomedical Engineering from Oxford Brooks University, and an EMBA from University of Minnesota.

 

FengJiangFeng Jiang
Executive Vice President
China Association for Medical Devices Industry


Doctor of Medicine, Executive vice president of China Association for Medical Devices Industry. Chairman of China Service Alliance of Medical Device Technology Innovation, Deputy director of the Steering Committee on Biomedical Engineering Education of the Ministry of Education, Standing director of China Biomedical Engineering Society, Standing director of China Biological Materials Society. He serves as consultant in many ministries, local governments and science parks, and serves as an independent director in many listed companies.